Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 3/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 9/20 | 0.40 |
| ▸ | CACNA1G | O43497 | 3/20 | 0.39 |
| ▸ | CACNA1H | O95180 | 3/20 | 0.39 |
| ▸ | CACNA1I | Q9P0X4 | 3/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | CLPP | Q16740 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6702369 | 0.76 | KDM4E (0.46) | PTGER4S1PR3CACNA1GCACNA1HCACNA1I | |
| SCHEMBL6699473 | 0.76 | MAOB (0.45) | PTGER4S1PR3CACNA1GCACNA1HCACNA1I | |
| SCHEMBL6696785 | 0.75 | MCHR1 (0.42) | PTGER4CACNA1GSIGMAR1CLPPNTRK1 | |
| SCHEMBL6696579 | 0.74 | CLPP (0.33) | SIGMAR1CLPPTP53 | |
| SCHEMBL6818720 | 0.72 | PTGER4 (0.50) | PTGER4CACNA1GCACNA1HCACNA1ITP53 | |
| SCHEMBL6704368 | 0.69 | ALDH1A1 (0.35) | PTGER4S1PR3CACNA1GCACNA1HCACNA1I | |
| SCHEMBL6288983 | 0.69 | PTGER4 (0.40) | PTGER4S1PR3CACNA1GCACNA1HCACNA1I | |
| SCHEMBL6292786 | 0.67 | KDM4E (0.51) | PTGER4S1PR3MAPTSMN1; SMN2 | |
| SCHEMBL6699557 | 0.66 | TP53 (0.47) | PTGER4CLPPTP53MAPTSMN1; SMN2 | |
| SCHEMBL6704242 | 0.66 | PTGER4 (0.36) | PTGER4CACNA1GCACNA1HCACNA1ISIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004014916-A1 | PYRIMIDINE FUSED BICYCLIC METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | claimed |
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | disclosed |
| WO-2004014916-A1 | PYRIMIDINE FUSED BICYCLIC METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | PTGER4 1609/4885S1PR3 1772/4885CACNA1G 4288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.